Pluri launches advanced global cell therapy CDMO

Pluri announced it has launched a new business division offering cell therapy manufacturing services as a Contract Development and Manufacturing Organization, CDMO,: PluriCDMO. PluriCDMO will offer its unique knowledge and technology and over 20 years of development and manufacturing experience. Its state-of-the-art 47 thousand square foot Good Manufacturing Practice cell therapy production facility is expected to help customers and partners address key challenges in the development and manufacturing of cell-based therapies. Pluri has appointed industry expert, Andy Lewin, to lead the business of its CDMO division. Pluri’s CEO and President Yaky Yanay said, “Opening the CDMO division is a strategic move that we expect will boost revenues and cash flow utilizing our well-established technology and manufacturing facility. PluriCDMO(TM)’s vision is to provide our clients with the best-in-class facility, but more importantly, the access to valuable knowledge in cell therapy development that has been generated over the last two decades. PluriCDMO(TM), as a high-end boutique CDMO, can accelerate the development efforts of our partners and provide better control of the risks. We believe that our proposition is strong and unique, working with PluriCDMO(TM) can be the launching pad that so many companies can benefit from. Our new CDMO division is another reflection of Pluri’s strategy to use our robust 3D cell expansion assets and in-house production facilities to create long-term value for our shareholders.”